Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

The Additive for the Bitumen on the Basis of the Modified Hydrolytic Lignin of the Organochlorine Wastes of the Chemical Industries

При производстве эпихлоргидрина из пропилена путем хлорирования, а также других аналогичных производств, например производства винилхлорида, хлористого аллила, дихлорэтана, образуется большое количество побочных хлорсодержащих органических соединений (ХОС). Это монохлорпропен, дихлорпропаны, дихлорпропены, трихлорпропаны и т.д. В силу своей токсичности ХОС не утилизируются микроорганизмами, поэтому их утилизация представляет собой серьезную технологическую и экологическую проблему. С целью повышения эффективности процесса связывания токсичных хлорорганических соединений лигнином с получением модифицирующей добавки для битума, обладающей повышенной совместимостью лигнина с битумом, лигнин активируют хлорной водой и полисульфидамиIn the production of the epichlorohydrin from the propylene by means of the chlorination, as well as the other similar industries such as the manufacture of the vinyl chloride, chlorallylene, dichloroethane form a large number of the accessory chlorinated organic compounds (ChOCs). These are the monohlorpropen, dichloropropane, dichloropropene, trichloropropane and so on. Because of its toxicity the chlorinated organic compounds are not utilized by the microorganisms, so their disposal is the major technological and ecological problems. In order to improve the efficiency of the process the banding of the toxic chlororganic compounds by the lignin to obtain the modifying additive for the bitumen, possessing the increased compatibility of the lignin with the bitumen, the lignin is activated with the chlorine water and polysulphide

The Additive for the Bitumen on the Basis of the Modified Hydrolytic Lignin of the Organochlorine Wastes of the Chemical Industries

При производстве эпихлоргидрина из пропилена путем хлорирования, а также других аналогичных производств, например производства винилхлорида, хлористого аллила, дихлорэтана, образуется большое количество побочных хлорсодержащих органических соединений (ХОС). Это монохлорпропен, дихлорпропаны, дихлорпропены, трихлорпропаны и т.д. В силу своей токсичности ХОС не утилизируются микроорганизмами, поэтому их утилизация представляет собой серьезную технологическую и экологическую проблему. С целью повышения эффективности процесса связывания токсичных хлорорганических соединений лигнином с получением модифицирующей добавки для битума, обладающей повышенной совместимостью лигнина с битумом, лигнин активируют хлорной водой и полисульфидамиIn the production of the epichlorohydrin from the propylene by means of the chlorination, as well as the other similar industries such as the manufacture of the vinyl chloride, chlorallylene, dichloroethane form a large number of the accessory chlorinated organic compounds (ChOCs). These are the monohlorpropen, dichloropropane, dichloropropene, trichloropropane and so on. Because of its toxicity the chlorinated organic compounds are not utilized by the microorganisms, so their disposal is the major technological and ecological problems. In order to improve the efficiency of the process the banding of the toxic chlororganic compounds by the lignin to obtain the modifying additive for the bitumen, possessing the increased compatibility of the lignin with the bitumen, the lignin is activated with the chlorine water and polysulphide

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)